CAH

Cardinal Health Inc. (CAH) | Rumor.io

Cardinal Health

CAH

Attention (50-day avg)0%

Attention rank (50-day avg)#1,069

Bullish sentiment (50-day avg)95%

Price to earnings ratio30.6

Market capitalization51B

Earnings per share7.22

Dividend yield (TTM)0.94%

Revenue (annual)254.2B

Net income (annual)1.7B

Social

What share of all stock conversation is about CAH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Aug 13

Cardinal Health, Inc. (CAH) recently involved in a dispute with SpaceX over land use, ultimately resulting in SpaceX vacating the land.
The dispute began when SpaceX contractors parked equipment on CAH's land, and CAH successfully sued for $15 million, which was settled before trial.
Despite this "victory", CAH's own land is now being annexed into the growing SpaceX-centered city, potentially limiting CAH's future development plans.

Generated by AI

Sentiment

Of the messages about CAH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +9.3	96.6% +11.66
Bearish	0%	0% 0	0% -9.3	3.4% -11.66

Bullish· Feb 5

Cardinal Health's Q2 earnings report exceeded expectations, with revenue increasing 19% to $65.6 billion and non-GAAP EPS rising 36% to $2.63.
The company raised its FY26 guidance, with non-GAAP EPS now expected to be between $10.15 and $10.35, beating consensus estimates.
Cardinal Health's stock price has been boosted by its strong earnings report, with some analysts predicting it could reach $120 this month.

Bearish· Aug 12

$CAH has missed Q2 revenue estimates, causing a 6.1% drop in stock price.
The company's acquisition of Solaris Health for $1.9 billion has raised concerns among investors, contributing to the stock's decline.
The stock's price has been affected by short positions taken deep out of the money, as well as the overall weakness in the US pharmaceutical stocks.

Generated by AI

Topics

Of the messages about CAH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	0%	20.99%
Earnings	0%	0%	32.43%	1.71%
Technical Analysis	100%	100%	2.7%	2.57%
Macro	0%	0%	32.43%	35.46%
Controversies	0%	0%	0%	0.28%
Analysts	0%	0%	32.43%	38.99%

Earnings· Feb 5

Cardinal Health reported Q2 FY2026 earnings with adjusted EPS of $2.63, a 36% YoY increase, and revenue of $65.6B, a 19% YoY increase.
The company raised its FY26 guidance for adjusted EPS to $10.15-$10.35, beating consensus estimates.
Cardinal Health's Q2 results were driven by strong double-digit revenue growth in its Pharmaceutical and Specialty Solutions segment, as well as broad-based segment profit expansion.

Analysts· Jun 9

Multiple analysts, including JPMorgan Chase, TD Cowen, and Evercore ISI, have raised their price targets for Cardinal Health (CAH) due to its investor day and updated guidance.
Price target upgrades for CAH range from $85 to $103, with analysts maintaining various ratings, including Neutral and Outperform.
Analysts are optimistic about CAH's long-term outlook, particularly in the Pharma segment, and see opportunities for growth, but some note that some news may be priced in.

Announcements· Jan 13

Cardinal Health ($CAH) raised its FY2026 non-GAAP EPS outlook to ≥$10.00, exceeding consensus estimates.
The company projects Specialty revenues to exceed $50 billion, driven by strong demand in bio pharma and its MSO platforms.
Cardinal Health also introduced its ContinuCare platform and completed the transition of distribution agreements for pharmaceuticals.

Controversies· Jul 20

The post raises questions about the role of medical distributors in the opioid epidemic, specifically mentioning $CAH, Cardinal Health, Inc.
The company's involvement in the opioid crisis is a topic of controversy.
Critics argue that companies like $CAH have a responsibility to address the issue.

Technical Analysis· Aug 6

$CAH's 50-day moving average is at 51.50, and a break above it is anticipated.
$CAH is trading near its 52-week low and offers a 4% dividend yield, making it an attractive opportunity for short-term gains.
A potential breakout for $CAH is expected, with a strong possibility of it flying above 55 if the company beats earnings and raises guidance.

Generated by AI

Community

Of the messages about CAH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	33.33%	17.99%	61%
Newcomers	50%	66.67%	82.01%	39%

Regulars· Aug 11

Cardinal Health reported Q4 2026 earnings of $2.91 per share, beating estimates by $0.49, but missing on revenue at $63.67 billion vs. $65B estimated.
The company guided FY27 earnings per share above consensus, at $12.50, and reported a 6% year-over-year revenue increase to $63.7 billion.
Cardinal Health's Q4 2026 revenue increased 6% year-over-year to $63.7 billion, with adjusted EPS of $2.91, a 40% year-over-year increase, and adjusted operating income of $935M, a 30% year-over-year increase.

Newcomers· Aug 13

CAH has been involved in a high-profile legal dispute with SpaceX, initially suing for $15 million.
CAH's goal was to be as problematic and annoying as possible, and they succeeded in being a nuisance to SpaceX.
Despite initially winning the dispute, CAH's own land is now being annexed into the SpaceX-centered city they were trying to obstruct.

Generated by AI

Even though Cardinal Health (currently trading at $220.37 per share) has gained 6.8% over the last six months, it has lagged the S&P 500’s 22.1% return during that period. This may have investors wondering how to approach the situation.

20h agoYahoo Finance

Cardinal Health (CAH) Stock Slides as Market Rises: Facts to Know Before You Trade

Cardinal Health (CAH) closed at $220.22 in the latest trading session, marking a -1.08% move from the prior day.

4d agoYahoo Finance

Cardinal Health Inc. stock underperforms Friday when compared to competitors

4d agoMarketWatch

Cardinal Health (CAH) Stock Looks About Right At Today’s Price

Cardinal Health has been a powerful performer over the past several years. The question now is whether the current share price lines up with what the business is earning. With the stock pulling back slightly in the short term after a strong multi year run, investors are increasingly focused on what its earnings actually justify. Cardinal Health has returned about 378.2% over the past 5 years, which puts real pressure on the current valuation story to be supported by the earnings profile. The...

5d agoYahoo Finance

Cardinal Health vs. McKesson: Which Healthcare Stock Is Better?

CAH's specialty-led growth, stronger EPS outlook and improving estimate momentum set up a compelling case against MCK.

5d agoYahoo Finance UK

Medical Textile Market Global Report 2026: A $39.53 Billion Revenue Surge to $64.28 Billion by 2030 at 26.9% CAGR, Benchmark 3M, Medline Industries, Cardinal Health, and DuPont to Secure Market Share

Profiles 3M, Medline, Cardinal Health, Medtronic and DuPont, covering competitors, segments, regional shares, trends and opportunities. Medical Textile Market Medical Textile Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Medical Textile Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Medical Textile Market to Reach $64.28 Billion by 2030 as Healthcare Demand Accelerates The global medical textile market is experiencing exponential growth, supported by rising

7d agoYahoo Finance

Also Discussed

Investors talking about CAH also mention

#	Name	Attention
1	Pacer Trendpilot Fund of Funds ETFTRND	0%new
2	McKesson CorporationMCK	0%0
3	Acquirers Funds, LLC - The Acquirers Fund ETFZIG	0.05%-1.17
4	NFNT - Infinite Acquisition Corp.	——
5	CSCI - COSCIENS Biopharma Inc.	——
6	ADEX - Adit EdTech Acquisition Corp.	——
7	Tron Inc.SRM	0%0
8	Rain Enhancement Technologies Holdco, Inc. Class A Common StockRAIN	0%0
9	Cencora Inc.COR	0%0
10	ABC - AmerisourceBergen Corporation	——

Cardinal Health Inc.

Healthcare
Medical Distribution

Cardinal Health Inc. is a healthcare services and products company that supports hospitals, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients at home. It distributes branded, generic, specialty, and over-the-counter pharmaceuticals, while also providing pharmacy management, inventory, logistics, and data-driven supply chain services. The company manufactures and distributes medical, surgical, and laboratory products, including procedure kits, gloves, needles, wound care items, and other clinical supplies. Cardinal Health also operates specialty pharmacy and radiopharmaceutical services that support complex care settings. Through its two main segments, Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution, Cardinal Health plays a central role in connecting manufacturers, providers, and care sites across the healthcare supply chain.

Website

Location

7000 Cardinal Place

Dublin, OH, 43017

United States

Social

What share of all stock conversation is about CAH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Aug 13

Cardinal Health, Inc. (CAH) recently involved in a dispute with SpaceX over land use, ultimately resulting in SpaceX vacating the land.
The dispute began when SpaceX contractors parked equipment on CAH's land, and CAH successfully sued for $15 million, which was settled before trial.
Despite this "victory", CAH's own land is now being annexed into the growing SpaceX-centered city, potentially limiting CAH's future development plans.

Generated by AI

Sentiment

Of the messages about CAH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +9.3	96.6% +11.66
Bearish	0%	0% 0	0% -9.3	3.4% -11.66

Bullish· Feb 5

Cardinal Health's Q2 earnings report exceeded expectations, with revenue increasing 19% to $65.6 billion and non-GAAP EPS rising 36% to $2.63.
The company raised its FY26 guidance, with non-GAAP EPS now expected to be between $10.15 and $10.35, beating consensus estimates.
Cardinal Health's stock price has been boosted by its strong earnings report, with some analysts predicting it could reach $120 this month.

Bearish· Aug 12

$CAH has missed Q2 revenue estimates, causing a 6.1% drop in stock price.
The company's acquisition of Solaris Health for $1.9 billion has raised concerns among investors, contributing to the stock's decline.
The stock's price has been affected by short positions taken deep out of the money, as well as the overall weakness in the US pharmaceutical stocks.

Generated by AI

Topics

Of the messages about CAH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	0%	20.99%
Earnings	0%	0%	32.43%	1.71%
Technical Analysis	100%	100%	2.7%	2.57%
Macro	0%	0%	32.43%	35.46%
Controversies	0%	0%	0%	0.28%
Analysts	0%	0%	32.43%	38.99%

Earnings· Feb 5

Cardinal Health reported Q2 FY2026 earnings with adjusted EPS of $2.63, a 36% YoY increase, and revenue of $65.6B, a 19% YoY increase.
The company raised its FY26 guidance for adjusted EPS to $10.15-$10.35, beating consensus estimates.
Cardinal Health's Q2 results were driven by strong double-digit revenue growth in its Pharmaceutical and Specialty Solutions segment, as well as broad-based segment profit expansion.

Analysts· Jun 9

Multiple analysts, including JPMorgan Chase, TD Cowen, and Evercore ISI, have raised their price targets for Cardinal Health (CAH) due to its investor day and updated guidance.
Price target upgrades for CAH range from $85 to $103, with analysts maintaining various ratings, including Neutral and Outperform.
Analysts are optimistic about CAH's long-term outlook, particularly in the Pharma segment, and see opportunities for growth, but some note that some news may be priced in.

Announcements· Jan 13

Cardinal Health ($CAH) raised its FY2026 non-GAAP EPS outlook to ≥$10.00, exceeding consensus estimates.
The company projects Specialty revenues to exceed $50 billion, driven by strong demand in bio pharma and its MSO platforms.
Cardinal Health also introduced its ContinuCare platform and completed the transition of distribution agreements for pharmaceuticals.

Controversies· Jul 20

The post raises questions about the role of medical distributors in the opioid epidemic, specifically mentioning $CAH, Cardinal Health, Inc.
The company's involvement in the opioid crisis is a topic of controversy.
Critics argue that companies like $CAH have a responsibility to address the issue.

Technical Analysis· Aug 6

$CAH's 50-day moving average is at 51.50, and a break above it is anticipated.
$CAH is trading near its 52-week low and offers a 4% dividend yield, making it an attractive opportunity for short-term gains.
A potential breakout for $CAH is expected, with a strong possibility of it flying above 55 if the company beats earnings and raises guidance.

Generated by AI

Community

Of the messages about CAH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	33.33%	17.99%	61%
Newcomers	50%	66.67%	82.01%	39%

Regulars· Aug 11

Cardinal Health reported Q4 2026 earnings of $2.91 per share, beating estimates by $0.49, but missing on revenue at $63.67 billion vs. $65B estimated.
The company guided FY27 earnings per share above consensus, at $12.50, and reported a 6% year-over-year revenue increase to $63.7 billion.
Cardinal Health's Q4 2026 revenue increased 6% year-over-year to $63.7 billion, with adjusted EPS of $2.91, a 40% year-over-year increase, and adjusted operating income of $935M, a 30% year-over-year increase.

Newcomers· Aug 13

CAH has been involved in a high-profile legal dispute with SpaceX, initially suing for $15 million.
CAH's goal was to be as problematic and annoying as possible, and they succeeded in being a nuisance to SpaceX.
Despite initially winning the dispute, CAH's own land is now being annexed into the SpaceX-centered city they were trying to obstruct.

Generated by AI

Cardinal Health

Social

Aug 13

Bullish· Feb 5

Bearish· Aug 12

Earnings· Feb 5

Analysts· Jun 9

Announcements· Jan 13

Controversies· Jul 20

Technical Analysis· Aug 6

Regulars· Aug 11

Newcomers· Aug 13

Cardinal Health (CAH): Buy, Sell, or Hold Post Q2 Earnings?

Cardinal Health (CAH) Stock Slides as Market Rises: Facts to Know Before You Trade

Cardinal Health Inc. stock underperforms Friday when compared to competitors

Cardinal Health (CAH) Stock Looks About Right At Today’s Price

Cardinal Health vs. McKesson: Which Healthcare Stock Is Better?

Medical Textile Market Global Report 2026: A $39.53 Billion Revenue Surge to $64.28 Billion by 2030 at 26.9% CAGR, Benchmark 3M, Medline Industries, Cardinal Health, and DuPont to Secure Market Share

Also Discussed

Cardinal Health Inc.

Company Information

Location

Cardinal Health (CAH): Buy, Sell, or Hold Post Q2 Earnings?

Cardinal Health (CAH) Stock Slides as Market Rises: Facts to Know Before You Trade

Cardinal Health Inc. stock underperforms Friday when compared to competitors

Cardinal Health (CAH) Stock Looks About Right At Today’s Price

Cardinal Health vs. McKesson: Which Healthcare Stock Is Better?

Medical Textile Market Global Report 2026: A $39.53 Billion Revenue Surge to $64.28 Billion by 2030 at 26.9% CAGR, Benchmark 3M, Medline Industries, Cardinal Health, and DuPont to Secure Market Share

Also Discussed

Social

Aug 13

Bullish· Feb 5

Bearish· Aug 12

Earnings· Feb 5

Analysts· Jun 9

Announcements· Jan 13

Controversies· Jul 20

Technical Analysis· Aug 6

Regulars· Aug 11

Newcomers· Aug 13